INO RSI Chart
Last 7 days
-0.8%
Last 30 days
-18.3%
Last 90 days
64.6%
Trailing 12 Months
4.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 12.3M | 13.7M | 4.9M | 4.9M |
2022 | 2.7M | 2.7M | 11.5M | 10.8M |
2021 | 8.3M | 8.2M | 7.6M | 2.8M |
2020 | 2.6M | 3.5M | 3.6M | 8.9M |
2019 | 31.8M | 7.5M | 6.3M | 4.1M |
2018 | 39.3M | 36.4M | 33.4M | 30.5M |
2017 | 37.6M | 51.8M | 41.9M | 42.2M |
2016 | 43.5M | 44.4M | 32.8M | 35.4M |
2015 | 13.3M | 14.8M | 37.1M | 40.6M |
2014 | 14.4M | 17.4M | 9.7M | 10.5M |
2013 | 3.9M | 4.2M | 12.9M | 13.5M |
2012 | 8.4M | 6.4M | 4.6M | 4.1M |
2011 | 7.9M | 9.2M | 10.5M | 9.8M |
2010 | 0 | 8.1M | 7.1M | 6.1M |
2009 | 0 | 0 | 0 | 9.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 26, 2024 | humeau laurent | sold (taxes) | -19,184 | 8.16 | -2,351 | chief scientific officer |
Feb 26, 2024 | shea jacqueline elizabeth | sold (taxes) | -30,420 | 8.16 | -3,728 | chief executive officer |
Feb 26, 2024 | kies peter | sold (taxes) | -28,282 | 8.16 | -3,466 | cfo |
Feb 26, 2024 | kies peter | acquired | - | - | 5,875 | cfo |
Feb 26, 2024 | weiner david b. | acquired | - | - | 2,916 | - |
Feb 26, 2024 | humeau laurent | acquired | - | - | 5,734 | chief scientific officer |
Feb 26, 2024 | shea jacqueline elizabeth | acquired | - | - | 7,731 | chief executive officer |
Jun 30, 2023 | sumner michael john | acquired | - | - | 35,000 | chief medical officer |
Jun 05, 2023 | zoth lota s. | sold | -3,192 | 0.56 | -5,700 | - |
May 16, 2023 | zoth lota s. | acquired | - | - | 19,000 | - |
Which funds bought or sold INO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | SIMPLEX TRADING, LLC | new | - | 92,000 | 92,000 | -% |
Apr 25, 2024 | Allworth Financial LP | sold off | -100 | -192 | - | -% |
Apr 25, 2024 | Bogart Wealth, LLC | sold off | -100 | -3.00 | - | -% |
Apr 25, 2024 | Allworth Financial LP | new | - | 431 | 431 | -% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -5,000 | - | -% |
Apr 25, 2024 | Bank of New York Mellon Corp | sold off | -100 | -66,855 | - | -% |
Apr 24, 2024 | Arlington Capital Management, Inc. | sold off | -100 | -14,145 | - | -% |
Apr 24, 2024 | Cambridge Investment Research Advisors, Inc. | sold off | -100 | -10,000 | - | -% |
Apr 24, 2024 | Newbridge Financial Services Group, Inc. | sold off | -100 | -2,040 | - | -% |
Apr 24, 2024 | Newbridge Financial Services Group, Inc. | new | - | 4,622 | 4,622 | -% |
Unveiling Inovio Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Inovio Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.3B | 2.4B | 91.05 | 6.31 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 5.8B | 396.6M | -10.93 | 14.57 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Inovio Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -73.6% | 102,651 | 388,446 | 2,168,233 | 2,207,171 | 124,666 | 9,154,133 | 857,667 | 669,814 | 839,115 | 291,698 | 928,111 | 769,237 | 5,580,581 | 896,710 | 1,067,399 | 1,327,274 | 279,488 | 866,863 | 135,674 | 2,829,905 | 2,502,624 |
Operating Expenses | -23.5% | 27,496,391 | 35,941,458 | 37,267,068 | 44,067,121 | 56,070,821 | 44,911,177 | 104,921,721 | 71,932,069 | 106,347,454 | 60,244,852 | 83,474,759 | 52,925,612 | 34,920,019 | 36,565,618 | 33,448,085 | 26,559,542 | 30,700,541 | 24,818,650 | 28,336,367 | 31,364,917 | 32,001,788 |
S&GA Expenses | 3.2% | 10,243,341 | 9,925,055 | 13,523,098 | 13,890,610 | 13,950,944 | 11,824,047 | 48,456,836 | 15,953,458 | 14,048,635 | 13,156,183 | 12,666,341 | 13,881,194 | 8,617,458 | 10,110,506 | 11,071,510 | 7,448,354 | 8,696,586 | 5,681,441 | 5,850,101 | 6,975,029 | 5,636,141 |
R&D Expenses | 11.3% | 17,253,050 | 15,503,032 | 23,743,970 | 30,176,511 | 42,119,877 | 33,087,130 | 56,464,885 | 55,978,611 | 92,298,819 | 47,088,669 | 70,808,418 | 39,044,418 | 26,302,561 | 26,455,112 | 22,376,575 | 19,111,188 | 22,003,955 | 19,137,209 | 22,486,266 | 24,389,888 | 26,365,647 |
EBITDA Margin | 17.8% | -26.98 | -32.81 | -12.01 | -19.18 | -25.24 | -28.21 | -130 | -117 | -105 | -28.19 | -16.00 | -20.98 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -9.9% | 282,325 | 313,488 | 313,488 | 313,488 | 313,488 | 313,488 | 313,488 | 313,488 | 480,313 | 476,374 | 466,726 | 513,034 | 1,068,008 | 1,984,046 | 2,846,641 | 2,803,755 | 2,668,837 | 2,428,671 | 2,194,783 | 656,248 | -156,261 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -87,764 | - | -106,771 | -62,800 | - |
Earnings Before Taxes | 26.3% | -25,003,638 | -33,929,864 | -35,534,533 | -40,649,317 | -54,463,139 | -37,783,896 | -108,497,311 | -76,908,506 | -106,947,580 | -60,169,041 | -82,139,958 | -53,967,744 | -22,415,201 | 20,931,010 | -128,270,709 | -33,135,404 | -38,235,146 | -23,536,452 | -29,685,847 | -29,351,667 | -32,962,205 |
EBT Margin | 17.5% | -27.76 | -33.67 | -12.34 | -19.56 | -25.69 | -28.66 | -132 | -119 | -107 | -28.89 | -16.83 | -22.10 | - | - | - | - | - | - | - | - | - |
Net Income | 26.3% | -25,003,638 | -33,929,864 | -35,534,533 | -40,649,317 | -54,463,139 | -37,783,896 | -108,497,311 | -79,073,719 | -106,947,580 | -60,169,041 | -82,139,958 | -54,402,131 | -24,338,380 | 19,171,336 | -129,172,466 | -33,135,404 | -37,662,038 | -23,090,693 | -29,387,226 | -29,219,262 | -32,962,205 |
Net Income Margin | 17.5% | -27.76 | -33.66 | -12.33 | -19.55 | -25.89 | -28.84 | -133 | -120 | -107 | -29.20 | -17.34 | -22.70 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 9.7% | -26,275,785 | -29,110,632 | -32,338,571 | -36,961,461 | -36,505,141 | -67,552,146 | -51,245,185 | -61,882,102 | -38,534,821 | -46,659,317 | -78,667,141 | -53,078,252 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -11.5% | 171 | 193 | 233 | 267 | 349 | 392 | 459 | 446 | 496 | 536 | 592 | 655 | 540 | 438 | 443 | 339 | 144 | 152 | 165 | 191 | 131 |
Current Assets | -12.4% | 153 | 175 | 203 | 234 | 315 | 350 | 416 | 400 | 448 | 487 | 542 | 588 | 471 | 377 | 382 | 276 | 94.00 | 99.00 | 111 | 135 | 88.00 |
Cash Equivalents | -23.9% | 14.00 | 19.00 | 53.00 | 28.00 | 46.00 | 22.00 | 41.00 | 59.00 | 71.00 | 68.00 | 59.00 | 84.00 | 251 | 179 | 215 | 158 | 22.00 | 16.00 | 20.00 | 21.00 | 24.00 |
Net PPE | -11.9% | 5.00 | 6.00 | 6.00 | 7.00 | 8.00 | 16.00 | 16.00 | 17.00 | 17.00 | 18.00 | 18.00 | 11.00 | 11.00 | 11.00 | 11.00 | 12.00 | 13.00 | 14.00 | 14.00 | 15.00 | 16.00 |
Goodwill | - | - | - | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 |
Liabilities | -2.4% | 54.00 | 55.00 | 64.00 | 67.00 | 126 | 125 | 162 | 90.00 | 96.00 | 82.00 | 83.00 | 73.00 | 79.00 | 114 | 257 | 151 | 139 | 115 | 109 | 110 | 44.00 |
Current Liabilities | -2.6% | 43.00 | 44.00 | 52.00 | 55.00 | 97.00 | 95.00 | 131 | 59.00 | 66.00 | 51.00 | 52.00 | 42.00 | 42.00 | 41.00 | 38.00 | 32.00 | 32.00 | 20.00 | 24.00 | 27.00 | 35.00 |
Long Term Debt | - | - | - | - | - | 17.00 | 16.00 | 17.00 | 16.00 | 15.00 | 14.00 | 15.00 | 14.00 | 5.00 | 4.00 | 14.00 | 13.00 | 64.00 | 8.00 | 63.00 | 61.00 | - |
LT Debt, Current | 1.7% | 17.00 | 16.00 | 17.00 | 16.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | 17.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -15.1% | 117 | 138 | 169 | 199 | 222 | 267 | 298 | 355 | 400 | 454 | 509 | 582 | 461 | 324 | 186 | 188 | 5.00 | 36.00 | 56.00 | 81.00 | 87.00 |
Retained Earnings | -1.4% | -1,622 | -1,600 | -1,600 | -1,500 | -1,487 | -1,433 | -1,395 | -1,287 | -1,209 | -1,102 | -1,042 | -960 | -906 | -881 | -901 | -772 | -739 | -702 | -679 | -649 | -620 |
Additional Paid-In Capital | 0.3% | 1,741 | 1,737 | 1,734 | 1,728 | 1,711 | 1,701 | 1,694 | 1,642 | 1,610 | 1,557 | 1,551 | 1,542 | 1,367 | 1,206 | 1,088 | 958 | 743 | 735 | 732 | 727 | 708 |
Shares Outstanding | 3.7% | 23.00 | 22.00 | 22.00 | 22.00 | 21.00 | 21.00 | 20.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 4.00 | 2.00 | 2.00 | 3.00 | 3.00 | 0.00 |
Float | - | - | - | 120 | - | - | - | 426 | - | - | - | 1,900 | - | - | - | 4,200 | - | - | - | 280 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 9.7% | -26,275 | -29,110 | -32,314 | -36,664 | -36,340 | -67,465 | -50,527 | -61,882 | -37,891 | -46,490 | -78,459 | -52,867 | -51,216 | -74,158 | -27,151 | -25,452 | -13,737 | -27,733 | -23,924 | -32,454 | -17,281 |
Share Based Compensation | 9.0% | 2,266 | 2,079 | 2,918 | 3,809 | 3,274 | 3,234 | 8,336 | 7,711 | 5,474 | 5,620 | 5,646 | 9,596 | 3,825 | 4,158 | 3,662 | 4,002 | 2,034 | 2,080 | 3,355 | 3,433 | 2,138 |
Cashflow From Investing | 463.0% | 19,943 | -5,493 | 53,907 | 19,000 | 54,001 | 44,557 | -10,304 | 21,332 | -6,493 | 55,958 | 50,306 | -275,115 | -3,716 | 39,115 | -42,385 | -51,808 | 10,435 | 8,270 | 21,588 | -49,337 | 7,183 |
Cashflow From Financing | 163.1% | 1,838 | 699 | 2,883 | -424 | 6,668 | 3,812 | 42,939 | 28,422 | 47,595 | -440 | 3,441 | 160,903 | 126,939 | -1,695 | 126,523 | 213,513 | 9,645 | 15,581 | 1,294 | 78,877 | 14,394 |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||||
---|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |||
Revenues [Abstract] | |||||
Revenue from collaborative arrangements and other contracts, including affiliated entity | $ 832,010 | $ 10,262,268 | $ 1,774,758 | ||
Operating expenses: | |||||
Research and development | 86,676,563 | 187,650,503 | 249,240,324 | ||
General and administrative | 47,582,104 | 90,185,285 | 53,752,353 | ||
Impairment of goodwill | 10,513,371 | 0 | 0 | ||
Total operating expenses | 144,772,038 | 277,835,788 | 302,992,677 | ||
Loss from operations | (143,940,028) | (267,573,520) | (301,217,919) | ||
Other income (expense): | |||||
Interest income | 8,133,290 | 4,782,030 | 3,363,080 | ||
Interest expense | (1,222,789) | (1,253,952) | (1,936,447) | ||
Gain (loss) on investment in affiliated entity | 773,145 | (1,899,654) | (553,570) | ||
Net unrealized gain (loss) on available-for-sale equity securities | 5,850,626 | (7,846,172) | (3,222,838) | ||
Other (expense) income, net | (4,711,596) | (3,861,584) | 343,371 | ||
Net loss before share in net loss of Geneos | (135,117,352) | (277,652,852) | (303,224,323) | ||
Share in net loss of Geneos | 0 | (2,165,213) | (434,387) | ||
Net loss | $ (135,117,352) | $ (279,818,065) | $ (303,658,710) | ||
Net loss per share | |||||
Basic (in dollars per share) | [1] | $ (6.09) | $ (14.07) | $ (17.45) | |
Diluted (in dollars per share) | [1] | $ (6.09) | $ (14.07) | $ (17.45) | |
Weighted average number of common shares outstanding | |||||
Basic (in shares) | [1] | 22,173,662 | 19,885,182 | 17,402,483 | |
Diluted (in shares) | [1] | 22,173,662 | 19,885,182 | 17,402,483 | |
|
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 | ||
---|---|---|---|---|
Current assets: | ||||
Cash and cash equivalents | $ 14,310,862 | $ 46,329,359 | ||
Short-term investments | 130,982,913 | 206,669,397 | ||
Prepaid expenses and other current assets | 5,393,665 | 50,130,481 | ||
Prepaid expenses and other current assets from affiliated entities | 20,432 | 375,227 | ||
Total current assets | 153,113,100 | 315,242,680 | ||
Fixed assets, net | 4,960,986 | 7,727,997 | ||
Investments in affiliated entity | 2,780,287 | 2,007,142 | ||
Intangible assets, net | 0 | 2,129,861 | ||
Goodwill | 0 | 10,513,371 | ||
Operating lease right-of-use assets | 9,491,735 | 10,228,207 | ||
Other assets | 605,315 | 684,044 | ||
Total assets | 170,951,423 | 348,533,302 | ||
Current liabilities: | ||||
Accrued clinical trial expenses | 2,365,382 | 10,594,073 | ||
Operating lease liability | 2,406,522 | 2,803,973 | ||
Grant funding liability | 87,489 | 2,475,031 | ||
Grant funding liability from affiliated entities | 21,918 | 87,673 | ||
Convertible senior notes | 16,770,654 | 0 | ||
Total current liabilities | 42,570,228 | 96,868,074 | ||
Convertible senior notes | 0 | 16,614,840 | ||
Operating lease liability, net of current portion | 11,032,066 | 12,655,586 | ||
Deferred tax liabilities | 0 | 32,046 | ||
Total liabilities | 53,602,294 | 126,170,546 | ||
Commitments and contingencies | ||||
Inovio Pharmaceuticals, Inc. stockholders’ equity: | ||||
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2023 and 2022 | 0 | 0 | ||
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2023 and 2022, issued and outstanding: 22,793,075 at December 31, 2023 and 21,090,938 at December 31, 2022 | [1] | 22,792 | 21,090 | |
Additional paid-in capital | 1,740,954,074 | 1,710,888,191 | ||
Accumulated deficit | (1,622,965,136) | (1,487,847,784) | ||
Accumulated other comprehensive loss | (662,601) | (698,741) | ||
Total Inovio Pharmaceuticals, Inc. stockholders’ equity | 117,349,129 | 222,362,756 | ||
Total liabilities and stockholders’ equity | 170,951,423 | 348,533,302 | ||
Nonrelated Party | ||||
Current assets: | ||||
Accounts receivable | 0 | 1,701,726 | ||
Current liabilities: | ||||
Accounts payable and accrued expenses | 19,847,744 | 79,686,885 | ||
Related Party | ||||
Current assets: | ||||
Accounts receivable | 2,405,228 | 10,036,490 | ||
Current liabilities: | ||||
Accounts payable and accrued expenses | $ 1,070,519 | $ 1,220,439 | ||
|